Compare Quest Diagnostics Inc (DGX) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Orion Office REIT Inc — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Orion Office REIT Inc trades at $2.7 (market cap $151.17M). The key difference: Quest Diagnostics Inc is far larger — about 150.8× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.01%). Which is the better fit depends on your goals.
| DGX | ONL | |
|---|---|---|
Market Cap | $22.80B | $151.17M |
Sector | Health | Real Estate |
52-Week High | $216.02 | $3.04 |
52-Week Low | $166.42 | $1.93 |
Enterprise Value | $28.82B | $634.82M |
Dividend Yield | 1.67% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ONL trades at $2.72, down 1.09% today, with a bearish technical signal and negative earnings momentum. The company reported Q1 2026 EPS of -$0.24, missing expectations, while revenue declined to $147.65M in 2025. Despite a low P/B of 0.25, profitability remains weak with a -98.36% net margin. Recent news highlights strategic reviews and portfolio repositioning toward dedicated-use assets.
The outlook is cautious due to persistent losses and declining revenue, though strategic asset sales and debt management provide some stability. Risks include high leverage and office market challenges. Analyst sentiment is mixed with 50% buy ratings. Investment opportunity hinges on successful execution of strategic initiatives amid a difficult operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
